Unum Therapeutics Inc (NASDAQ:UMRX) Q4 2018 Earnings Conference Call - Final Transcript
Mar 28, 2019 • 08:00 am ET
Good day, ladies and gentlemen, and welcome to the Unum Therapeutics Fourth Quarter 2018 Results Conference Call. At this time, all participants are in a listen only mode lady. Later we will conduct a question and answer session and instructions will follow at that time. (Operator Instructions) I would now like to hand the call over to Ms. Stephanie Ascher. You may begin.
Good morning, and welcome to the Unum Therapeutics' quarterly investor conference call. Today, we'll be sharing updates on our Company's progress and our financial results for the fourth quarter, ended December, 31st, 2018, and full year of 2018. With me on our call today are Chuck Wilson, CEO, Michael Vasconcelles, Chief Medical Officer, Seth Ettenberg, Chief Scientific Officer, and John Green, Vice President of Finance. Following our prepared remarks, we'll open the line for questions.
Before we begin our prepared remarks, I need to remind you that estimates and other forward looking statements included in this call represent the Company's view as of today, March 28, 20 19. Unum Therapeutics disclaims any obligation to update these statements to reflect future events or circumstances. Please refer today's press release, as well as Unum's filings with the SEC for information concerning risk factors that could cause actual results to differ materially from those expressed or implied by such statements. Please also note that this call is being simultaneously webcast online.
With that, let me introduce, Chuck Wilson, CEO. Chuck?
Good morning. I'm pleased to be able to provide a number of updates today, reporting progress across several fronts, including advances in our clinical stage programs in lymphoma and myeloma and the rapid expansion of our solid tumor pipeline. Mike will provide you with an update on our ongoing clinical trials. And Seth will talk about our research efforts to expand our technology platform with a particular focus on targeting solid tumors. We'll then conclude with a summary of our financial performance by John, and key milestones for 2019.
We made important progress across our entire pipeline in 2018, and look forward to building upon that in 2019. In our programs targeting hematologic cancers, we see a clear path to establishing potential best-in-class product profiles that may compete effectively with other approved and investigational products. In our solid tumor programs, we see a unique opportunity for our technology platforms to address the historical challenges that T-Cell therapies have faced in this setting, using truly novel approaches.
Among the key highlights we'll be talking about today, we continue to be pleased with the safety and activity that we've seen to-date with ACTR in non-Hodgkin lymphoma and our decision to move forward with ACTR707 in this indication. Mike will summarize the data that we shared at ASH in December and provide some updates in terms of where we stand today.
We've also made good progress in wrapping up the ATTCK-22 study, which has positively impacted our runway, as John, our VP Finance, will describe later. In our collaboration with Seattle Genetics to develop